Loading...
BioHarvest Sciences Inc.
BHSC.CN•CNQ
Healthcare
Drug Manufacturers - Specialty & Generic
CA$7.95
CA$0.00(0.00%)

Financial performance has remained strong, with revenue growing from $4.52M in Q4 2023 to $6.54M in Q3 2024. Gross profit continued to perform well, with margins at 57% in the latest quarter. Operating income reached -$2.10M in Q3 2024, holding a steady -32% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$1.75M. Net income dropped to -$2.69M, keeping EPS at $0.00. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan